Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma.

Nadia GagnonSophie BernardMartine PaquetteCatherine AlguireAndré LacroixPierre-Olivier HétuHarold J OlneyIsabelle Bourdeau

Published in: Endocrine oncology (Bristol, England) (2022)

The introduction of mitotane produces a clinically significant elevation of lipid parameters (LDL-c, HDL-c, Tg and non-HDL-c) during the first year of treatment.

Keyphrases

high fat diet
type diabetes
fatty acid
metabolic syndrome
smoking cessation